title: Pharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy Volunteer Studies.
abstract: This report describes the safety, immunogenicity, and pharmacokinetic results of obiltoxaximab treatment in healthy subjects from 5 clinical trials.
  
  
  
  Healthy men and women were enrolled in randomized, double-blind studies of obiltoxaximab versus placebo (studies 1-3), an open-label, parallel-group study of obiltoxaximab alone versus obiltoxaximab and ciprofloxacin (study 4), or a randomized, double-blind, placebo-controlled study involving administration of a second dose of obiltoxaximab 13 or 119 days after an initial dose (study 5). Obiltoxaximab was administered intravenously in all studies. The safety profile was characterized by physical examinations, including focused examinations of the skin and infusion sites; study drug infusion discontinuations; and assessment of adverse events, vital signs, electrocardiographic findings, laboratory parameters, and immunogenicity. Studies 3 to 5 were the primary safety profile studies. Pharmacokinetic parameters were calculated using noncompartmental methods.
  
  
  
  Results of 2 multiple dose studies (studies 1 and 2) revealed that obiltoxaximab exposure increased proportionally. Pharmacokinetic results were consistent across studies. After administration of 16 mg/kg of obiltoxaximab, serum concentrations decreased in a biexponential or multiexponential fashion with a terminal half-life of 17 to 23 days. Mean volume of distribution was approximately 6.3 to 7.5 L, suggesting obiltoxaximab distribution outside the vascular compartment and potentially into tissues. Mean systemic clearance was approximately 0.27 L/d, suggesting that hepatic metabolism and/or renal excretion are not critical to obiltoxaximab elimination. Obiltoxaximab was generally well tolerated. Hypersensitivity reactions were the most common adverse reactions in the safety profile clinical trials, occurring in 34 of 320 subjects (10.6%) receiving obiltoxaximab and 4 of 70 subjects (5.7%) receiving placebo. The most common adverse events were headache, pruritus, upper respiratory tract infection, cough, infusion site swelling, bruising and/or pain, nasal congestion, urticaria, and extremity pain. Of the 320 subjects in the primary safety profile studies who received ≥1 dose of 16 mg/kg of obiltoxaximab, 8 (2.5%) tested positive for a exposure-emergent antiobiltoxaximab response; however, quantitative titers were low (1:20-1:320).
  
  
  
  On the basis of consistent results of 5 clinical trials in healthy volunteers, the pharmacokinetic properties of obiltoxaximab after a 16-mg/kg IV infusion can be considered adequately characterized, a criteria of the Animal Rule. Obiltoxaximab appears to be generally well tolerated. ClinicalTrials.gov identifiers: NCT00829582, NCT01453907, NCT01929226, NCT01952444, NCT01932242.
authors: Department of Clinical Operations, Elusys Therapeutics, Inc, Pine Brook, New Jersey. Electronic address: cnagy@elusys.com.
authors: Christa F
authors: CF
authors: Nagy
authors: InterimMD, Inc, Groton, Massachusetts.
authors: Timothy S
authors: TS
authors: Leach
authors: Hoffman Consulting LLC, Park Ridge, New Jersey.
authors: Joseph H
authors: JH
authors: Hoffman
authors: Department of Clinical Operations, Elusys Therapeutics, Inc, Pine Brook, New Jersey.
authors: Arthur
authors: A
authors: Czech
authors: Department of Research and Nonclinical Development, Elusys Therapeutics, Inc, Pine Brook, New Jersey.
authors: Sarah E
authors: SE
authors: Carpenter
authors: Aclairo Pharmaceutical Development Group, Inc, Vienna, Virginia.
authors: Robert
authors: R
authors: Guttendorf
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood*; D000992:Antitoxins / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood*; D019540:Area Under Curve; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004342:Drug Hypersensitivity / Q000209:etiology; D005260:Female; D006207:Half-Life; D006261:Headache / Q000139:chemically induced; D064368:Healthy Volunteers; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D000992:Antitoxins; C000611266:obiltoxaximab
keywords: animal rule; anthrax; monoclonal antibody; obiltoxaximab; pharmacokinetic properties